OncoCyte Corporation Set to Join Russell 3000® Index
June 12 2017 - 7:00AM
OncoCyte Corporation (NYSE MKT:OCX), a developer
of novel, non-invasive blood-based liquid biopsy tests for the
early detection of cancer, announced today that the Company is set
to join the broad-market Russell 3000® Index at the conclusion of
the Russell indexes annual reconstitution, effective after the U.S.
market opens on June 26.
“The preliminary addition of OncoCyte to the
Russell 3000 Index is a testament to the progress we have made in
building value for our shareholders through the development of
novel cancer diagnostic products,” said William Annett, Chief
Executive Officer. “Inclusion in the Russell 3000 Index will help
expand awareness of our Company, especially among institutional
investors, as we continue to execute our development and
commercialization programs.”
Annual Russell indexes reconstitution captures
the largest U.S. stocks as of the end of May, ranking them by total
market capitalization. Membership in the U.S. all-cap Russell 3000®
Index, which remains in place for one year, means automatic
inclusion in the large-cap Russell 1000® Index or small-cap Russell
2000® Index as well as the appropriate growth and value style
indexes. FTSE Russell determines membership for its Russell indexes
primarily by objective, market-capitalization rankings and style
attributes. The information concerning OncoCyte was posted by
Russell Investments on June 9, 2017.
Russell indexes are widely used by investment
managers and institutional investors for index funds and as
benchmarks for active investment strategies. Approximately $8.4
trillion in assets are benchmarked against Russell’s U.S. indexes.
Russell indexes are part of FTSE Russell, a leading global index
provider.
For more information on the Russell indexes
reconstitution, please visit the FTSE Russell website.
About OncoCyte Corporation
OncoCyte is focused on the development and
commercialization of novel, non-invasive blood and urine (“liquid
biopsy”) diagnostic tests for the early detection of cancer to
improve health outcomes through earlier diagnoses, to reduce the
cost of care through the avoidance of more costly diagnostic
procedures, including invasive biopsy and cystoscopic procedures,
and to improve the quality of life for cancer patients. While
current biopsy tests use invasive surgical procedures to provide
tissue samples in order to determine if a tumor is benign or
malignant, OncoCyte is developing a next generation of diagnostic
tests that will be based on liquid biopsies using blood or urine
samples. OncoCyte’s pipeline products are intended to be
confirmatory diagnostics for detecting lung, breast and bladder
cancer. OncoCyte’s diagnostic tests are being developed using
proprietary sets of genetic and protein markers that differentially
express in specific types of cancer.
Forward Looking Statements
Any statements that are not historical fact
(including, but not limited to statements that contain words such
as “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates” and similar expressions) are forward-looking
statements. These statements include those pertaining to the
implementation and results of our future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for OncoCyte, along with
other statements about the future expectations, beliefs, goals,
plans, or prospects expressed by management. Forward-looking
statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or
commercialization of potential diagnostic tests or products,
uncertainty in the results of clinical trials or regulatory
approvals, the need and ability to obtain future capital, and
maintenance of intellectual property rights, and the need to obtain
third party reimbursement for patient’s use of any diagnostic tests
we commercialize. Actual results may differ materially from the
results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that
affect the business of OncoCyte, particularly those mentioned in
the “Risk Factors” and other cautionary statements found in
OncoCyte’s Securities and Exchange Commission filings. OncoCyte
disclaims any intent or obligation to update these forward-looking
statements, except as required by law.
Investor Contact:
EVC Group, Inc.
Doug Sherk / Matt Haines
646-445-4800
dsherk@evcgroup.com / mhaines@evcgroup.com
Financial Media Contact:
GIBSON Communications, LLC
Tom Gibson
201-476-0322
tom@tomgibsoncommunications.com